502 related articles for article (PubMed ID: 25230289)
1. Distinct natural killer cells in HIV-exposed seronegative subjects with effector cytotoxic CD56(dim) and CD56(bright) cells and memory-like CD57⁺NKG2C⁺CD56(dim) cells.
Lima JF; Oliveira LM; Pereira NZ; Mitsunari GE; Duarte AJ; Sato MN
J Acquir Immune Defic Syndr; 2014 Dec; 67(5):463-71. PubMed ID: 25230289
[TBL] [Abstract][Full Text] [Related]
2. Impaired natural killer cell responses are associated with loss of the highly activated NKG2A(+)CD57(+)CD56(dim) subset in HIV-1 subtype D infection in Uganda.
Naluyima P; Eller MA; Laeyendecker O; Quinn TC; Serwadda D; Sewankambo NK; Gray RH; Michael NL; Wabwire-Mangen F; Robb ML; Sandberg JK
AIDS; 2014 Jun; 28(9):1273-8. PubMed ID: 24959961
[TBL] [Abstract][Full Text] [Related]
3. Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals.
Tarazona R; Casado JG; Delarosa O; Torre-Cisneros J; Villanueva JL; Sanchez B; Galiani MD; Gonzalez R; Solana R; Peña J
J Clin Immunol; 2002 May; 22(3):176-83. PubMed ID: 12078859
[TBL] [Abstract][Full Text] [Related]
4. Circulating NK cells and their subsets in Behçet's disease.
Hasan MS; Ryan PL; Bergmeier LA; Fortune F
Clin Exp Immunol; 2017 May; 188(2):311-322. PubMed ID: 28170096
[TBL] [Abstract][Full Text] [Related]
5. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets.
Yu J; Mao HC; Wei M; Hughes T; Zhang J; Park IK; Liu S; McClory S; Marcucci G; Trotta R; Caligiuri MA
Blood; 2010 Jan; 115(2):274-81. PubMed ID: 19897577
[TBL] [Abstract][Full Text] [Related]
6. The early expansion of anergic NKG2A
Roberto A; Di Vito C; Zaghi E; Mazza EMC; Capucetti A; Calvi M; Tentorio P; Zanon V; Sarina B; Mariotti J; Bramanti S; Tenedini E; Tagliafico E; Bicciato S; Santoro A; Roederer M; Marcenaro E; Castagna L; Lugli E; Mavilio D
Haematologica; 2018 Aug; 103(8):1390-1402. PubMed ID: 29700172
[TBL] [Abstract][Full Text] [Related]
7. Polyfunctional natural killer cells with a low activation profile in response to Toll-like receptor 3 activation in HIV-1-exposed seronegative subjects.
Lima JF; Oliveira LMS; Pereira NZ; Duarte AJS; Sato MN
Sci Rep; 2017 Apr; 7(1):524. PubMed ID: 28373665
[TBL] [Abstract][Full Text] [Related]
8. Differential alteration of CD56(bright) and CD56 (dim) natural killer cells in frequency, phenotype, and cytokine response in chronic hepatitis C virus infection.
Miyagi T; Shimizu S; Tatsumi T; Nishio K; Hiramatsu N; Kanto T; Hayashi N; Takehara T
J Gastroenterol; 2011 Aug; 46(8):1020-30. PubMed ID: 21559771
[TBL] [Abstract][Full Text] [Related]
9. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.
Gonzalez VD; Falconer K; Björkström NK; Blom KG; Weiland O; Ljunggren HG; Alaeus A; Sandberg JK
J Immunol; 2009 Nov; 183(10):6612-8. PubMed ID: 19846870
[TBL] [Abstract][Full Text] [Related]
10. Terminal Differentiation of CD56(dim)CD16(+) Natural Killer Cells Is Associated with Increase in Natural Killer Cell Frequencies After Antiretroviral Treatment in HIV-1 Infection.
Ahmad F; Tufa DM; Mishra N; Jacobs R; Schmidt RE
AIDS Res Hum Retroviruses; 2015 Dec; 31(12):1206-12. PubMed ID: 26352913
[TBL] [Abstract][Full Text] [Related]
11. Alteration of inhibitory and activating NK cell receptor expression on NK cells in HIV-infected Chinese.
Jiang Y; He L; Chen H; Bice T; Zhang Z; Liu J; Ding H; Han X; Shang H
Cell Immunol; 2011; 271(2):219-26. PubMed ID: 21813117
[TBL] [Abstract][Full Text] [Related]
12. CD56
Judge CJ; Kostadinova L; Sherman KE; Butt AA; Falck-Ytter Y; Funderburg NT; Landay AL; Lederman MM; Sieg SF; Sandberg JK; Anthony DD
J Leukoc Biol; 2017 Jul; 102(1):171-184. PubMed ID: 28400540
[TBL] [Abstract][Full Text] [Related]
13. CD56negCD16⁺ NK cells are activated mature NK cells with impaired effector function during HIV-1 infection.
Milush JM; López-Vergès S; York VA; Deeks SG; Martin JN; Hecht FM; Lanier LL; Nixon DF
Retrovirology; 2013 Dec; 10():158. PubMed ID: 24351015
[TBL] [Abstract][Full Text] [Related]
14. NK Cell Activity and CD57
Flórez-Álvarez L; Blanquiceth Y; Ramírez K; Ossa-Giraldo AC; Velilla PA; Hernandez JC; Zapata W
Front Immunol; 2020; 11():537044. PubMed ID: 33042136
[TBL] [Abstract][Full Text] [Related]
15. A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature.
Cooley S; Xiao F; Pitt M; Gleason M; McCullar V; Bergemann TL; McQueen KL; Guethlein LA; Parham P; Miller JS
Blood; 2007 Jul; 110(2):578-86. PubMed ID: 17392508
[TBL] [Abstract][Full Text] [Related]
16. Increased natural killer cell subsets with inhibitory cytokines and inhibitory surface receptors in patients with recurrent miscarriage and decreased or normal subsets in kidney transplant recipients late post-transplant.
Zhu L; Aly M; Wang H; Karakizlis H; Weimer R; Morath C; Kuon RJ; Toth B; Ekpoom N; Opelz G; Daniel V
Clin Exp Immunol; 2018 Aug; 193(2):241-254. PubMed ID: 29679490
[TBL] [Abstract][Full Text] [Related]
17. Human natural killer cell maturation defect supports in vivo CD56(bright) to CD56(dim) lineage development.
Domaica CI; Fuertes MB; Uriarte I; Girart MV; Sardañons J; Comas DI; Di Giovanni D; Gaillard MI; Bezrodnik L; Zwirner NW
PLoS One; 2012; 7(12):e51677. PubMed ID: 23240056
[TBL] [Abstract][Full Text] [Related]
18. Killer Ig-like receptor (KIR) genotype predicts the capacity of human KIR-positive CD56dim NK cells to respond to pathogen-associated signals.
Korbel DS; Norman PJ; Newman KC; Horowitz A; Gendzekhadze K; Parham P; Riley EM
J Immunol; 2009 May; 182(10):6426-34. PubMed ID: 19414796
[TBL] [Abstract][Full Text] [Related]
19. Interferon-γ production by tubulointerstitial human CD56
Law BMP; Wilkinson R; Wang X; Kildey K; Lindner M; Rist MJ; Beagley K; Healy H; Kassianos AJ
Kidney Int; 2017 Jul; 92(1):79-88. PubMed ID: 28396119
[TBL] [Abstract][Full Text] [Related]
20. Perturbation of the natural killer cell compartment during primary human immunodeficiency virus 1 infection primarily involving the CD56 bright subset.
Mantegani P; Tambussi G; Galli L; Din CT; Lazzarin A; Fortis C
Immunology; 2010 Feb; 129(2):220-33. PubMed ID: 19824914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
